Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells
Authors:
Open Access
- 19 December 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 9, 1448
Abstract
IL12 is an immune-stimulatory cytokine for key immune cells including T cells and NK cells. However, systemic administration of IL12 has serious side effects that limit its clinical application in patients. Recently, synthetic Notch (synNotch) receptors have been developed that induce transcriptional activation and deliver therapeutic payloads in response to the reorganization of specific antigens. NK92 cell is a human natural killer (NK) cell line which has been developed as tools for adjuvant immunotherapy of cancer. Here, we explored the possibility of using synNotch receptor-engineered NK92 cells to selectively secrete IL12 at the tumor site and increase the antitumor activities of chimeric antigen receptor (CAR)-modified T cells. Compared with the nuclear factor of activated T-cells (NFATs) responsive promoter, which is another regulatory element, the synNotch receptor was better at controlling the expression of cytokines. NK92 cells transduced with the GPC3-specific synNotch receptor could produce the proinflammatory cytokine IL12 (GPC3-Syn-IL12-NK92) in response to GPC3 antigen expressed in cancer cells. In vivo GPC3-Syn-IL12-NK92 cells controlling IL12 production could enhance the antitumor ability of GPC3-redirected CAR T cells and increase the infiltration of T cells without inducing toxicity. Taken together, our results demonstrated that IL12 supplementation by synNotch-engineered NK92 cells could secrete IL12 in a target-dependent manner, and promote the antitumor efficiency of CAR-T cells. Local expression of IL12 by synNotch-engineered NK92 cells might be a safe approach to enhance the clinical outcome of CAR-T cell therapy.Keywords
Funding Information
- National Major Science and Technology Projects of China (2017ZX10203206006001)
- National Natural Science Foundation of China (31800659, 81872483)
This publication has 46 references indexed in Scilit:
- Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior ImmunotherapiesClinical Cancer Research, 2013
- Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resectionSurgery, 2013
- Evaluation of γ-Retroviral Vectors That Mediate the Inducible Expression of IL-12 for Clinical ApplicationJournal of Immunotherapy, 2012
- Improving Adoptive T Cell Therapy by Targeting and Controlling IL-12 Expression to the Tumor EnvironmentMolecular Therapy, 2011
- Innate or Adaptive Immunity? The Example of Natural Killer CellsScience, 2011
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative RegimensJournal of Clinical Oncology, 2008
- Immunotherapy of cancer by IL-12-based cytokine combinationsExpert Opinion on Biological Therapy, 2007
- Interferon regulatory factor‐1 is prerequisite to the constitutive expression and IFN‐γ‐induced upregulation of B7‐H1 (CD274)FEBS Letters, 2006
- Interleukin-12 and the regulation of innate resistance and adaptive immunityNature Reviews Immunology, 2003
- Clinical Trials: IL-12 Deaths: Explanation and a PuzzleScience, 1995